{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T13:39:33Z","timestamp":1777469973584,"version":"3.51.4"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.mehy.2020.109779","type":"journal-article","created":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T11:42:44Z","timestamp":1587555764000},"page":"109779","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["SARS \u2013 CoV-2: Reasons of epidemiology of severe ill disease cases and therapeutic approach using trivalent vaccine (tetanus, diphtheria and Bordetella pertussis)"],"prefix":"10.1016","volume":"141","author":[{"given":"Giuseppe","family":"Ietto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mehy.2020.109779_b0005","unstructured":"McIntosh K. Coronaviruses. Topic 8298 Version 51.0; UpToDate; 2020. https:\/\/www-uptodate-com\/contents\/coronaviruses?topicRef=126981&source=see_link; (accessed March 15 2020)."},{"key":"10.1016\/j.mehy.2020.109779_b0010","unstructured":"McIntosh K. Coronavirus disease 2019 (COVID-19). Topic 126981 Version 24.0; UpToDate; 2020. https:\/\/www-uptodate-com\/contents\/coronavirus-disease-2019-covid-19; (accessed March 15 2020)."},{"key":"10.1016\/j.mehy.2020.109779_b0015","unstructured":"W.H. Organization. Coronavirus disease COVID-19 outbreak. 2020."},{"key":"10.1016\/j.mehy.2020.109779_b0020","unstructured":"Age, Sex, Existing Conditions of COVID-19 Cases and Deaths. [cited 2020 February 29]."},{"key":"10.1016\/j.mehy.2020.109779_b0025","first-page":"15","article-title":"Influenza: the mother of all pandemics","volume":"2006","author":"Taubenberger","year":"1918","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.mehy.2020.109779_b0030","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-19-2062","article-title":"Exploiting pre-existing immunity to enhance oncolytic cancer immunotherapy","author":"Tahtinen","year":"2020","journal-title":"Cancer Res"},{"issue":"7543","key":"10.1016\/j.mehy.2020.109779_b0035","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/nature14320","article-title":"Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients","volume":"519","author":"Mitchell","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.mehy.2020.109779_b0040","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3389\/fimmu.2018.00014","article-title":"Recent advances in targeting CD8 t-cell immunity for more effective cancer immunotherapy","volume":"9","author":"Durgeau","year":"2018","journal-title":"Front Immunol"},{"issue":"7655","key":"10.1016\/j.mehy.2020.109779_b0045","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nature22395","article-title":"Therapeutic T cell engineering","volume":"545","author":"Sadelain","year":"2017","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.mehy.2020.109779_b0050","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00018-017-2686-7","article-title":"CD4 and CD8 T lymphocyte interplay in controlling tumor growth","volume":"75","author":"Ostroumov","year":"2018","journal-title":"Cell Mol Life Sci"},{"issue":"12","key":"10.1016\/j.mehy.2020.109779_b0055","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1084\/jem.188.12.2357","article-title":"The central role of CD4(+) T cells in the antitumor immune response","volume":"188","author":"Hung","year":"1998","journal-title":"J Exp Med"},{"issue":"8","key":"10.1016\/j.mehy.2020.109779_b0060","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1073\/pnas.90.8.3539","article-title":"Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity","volume":"90","author":"Dranoff","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"10.1016\/j.mehy.2020.109779_b0065","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41577-018-0044-0","article-title":"CD4(+) T cell help in cancer immunology and immunotherapy","volume":"18","author":"Borst","year":"2018","journal-title":"Nat Rev Immunol"},{"issue":"45","key":"10.1016\/j.mehy.2020.109779_b0070","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.15585\/mmwr.mm6645a3","article-title":"Global routine vaccination coverage, 2016","volume":"66","author":"Feldstein","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987720304242?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987720304242?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T19:23:38Z","timestamp":1759692218000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987720304242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":14,"alternative-id":["S0306987720304242"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2020.109779","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SARS \u2013 CoV-2: Reasons of epidemiology of severe ill disease cases and therapeutic approach using trivalent vaccine (tetanus, diphtheria and Bordetella pertussis)","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2020.109779","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109779"}}